Study of possible radioprotective properties of deanol aceglumate under the action of ionizing radiation on human cells

One of the effective methods to mitigate late side effects of radiotherapy is to use radioprotectors that reduce harmful effects of ionizing radiation on living cells. Nowadays there are no ideal and multifunctional radioprotectors. In this connection, the research priority is the search for new radioprotectors able to protect healthy cells from side effects of radiation therapy. A promising compound that can be used as a radioprotector is deanol aceglumate. Deanol aceglumate is known as a low-toxic nootropic drug. In addition, there is evidence of its hepatoprotective and antioxidant activity. The aim of the study is to investigate the potential properties of deanol aceglumate to protect human fibroblasts (hTERT) from gamma-radiation and C-12 ions and to select the optimal time of cell incubation with deanol aceglumate prior to irradiation. The effect of radiation was evaluated by the criteria of the time of cells doubling and cells clonogenic activity. It is shown that deanol aceglumate at a concentration of 1000 mcM has a radioprotective effect on human fibroblasts exposed to gamma radiation. The optimal time of the cells incubation prior to irradiation is 24 hours in order to achieve the highest radioprotective effect. Deanol aceglumate at a concentration of 1000 mcM does not protect normal cells when exposed to C-12 ions beyond Bragg Peak. It has been found that deanol aceglumate radioprotective properties depend significantly on the quality of ionizing radiation. The use of deanol aceglumate can be a promising way to reduce the ionizing radiation-induced diverse effect on normal human cells during radiation therapy of cancer patients.